CNS indication/ Endpoint prioritization

Less than 1 min read

Scroll

A biopharma client with an early clinical stage compound, showing efficacy across multiple neuropsychiatric conditions, wished to prioritize indications for ongoing clinical development

Through extensive primary/ secondary market research and literature review, we ranked each potential indication across multiple dimensions including epidemiology, burden of persistent unmet clinical need/ quality-of-life effects, complexity of standard clinical endpoints and symptom scores, likelihood of improvement, and on-market and pipeline competitive intensity

Highest ranking diseases (and respective endpoints) were prioritized by the Clinical Development and Medical Affairs teams for incorporation into the ongoing clinical trial program

More insights.

A large biopharma client objective aimed to optimize its omnichannel (OC) approach for HCP and patient Medical Education...

A top biopharma client wanted to understand diagnosis and treatment patterns for a rare respiratory disease only recently associated as a sequela....

A rare disease research consortium sought to identify barriers to adoption of AI-enabled, point-of-care diagnostic decision support tools..